Amgen Inc (HKSE:04332)
HK$ 1761 0 (0%) Market Cap: 1.17 Til Enterprise Value: 1.57 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 92/100

Amgen Inc To Acquire Horizon Therapeutics Transcript

Dec 12, 2022 / 01:00PM GMT
Release Date Price: HK$1850
Operator

Hello, and welcome. My name is Alex, and I will be your conference facilitator today for Amgen's acquisition of Horizon Therapeutics Conference Call. (Operator Instructions) I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr. Sood, you may now begin.

Arvind Sood;Robert A. Bradway
Amgen Inc. - VP of IR;Amgen Inc. - Chairman

Alex, thank you. Good morning, everybody. Thanks for joining us on such short notice. We wanted to take this opportunity to discuss the acquisition of Horizon Therapeutics that we announced earlier this morning. Joining me this morning is our Chairman and CEO, Bob Bradway, and other members of our senior leadership team. Our slide presentation is being posted on our website under the Investor Relations section as we speak.

I would like to direct you to our safe harbor statement on Slide 2, which in summary says that we'll make forward-looking statements through the course of our discussion today, and actual results can differ materially. So with that, over to you, Bob.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot